Safety of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data

figure

posted on 2020-08-07, 16:32 authored by Joseph A. Lasky, Gerard J. Criner, Howard M. Lazarus, Veronika Kohlbrenner, Shaun Bender, Luca Richeldi

Article full text

The above summary slide and graphical plain language summary represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

History

Usage metrics

Keywords

Interstitial lung diseases Monitoring, drug Postmarketing drug surveillance Tyrosine kinase inhibitor Plain Language Summary Graphical abstract infographic

Licence

CC BY-NC 4.0

Safety of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data

History

Usage metrics

Categories

Keywords

Licence

Exports